FDA Shelves Fast-Track Drug Voucher Program
Former U.S. Food and Drug Administration Commissioner Marty Makary’s fast-track drug review program, launched under the Trump administration, has been shelved, according to six sources familiar with the situation and documents.
Launched in June 2025, the Commissioner’s National Priority Voucher program aimed to slash drug review timelines to just one to two months for therapies addressing national priorities, such as urgent unmet health needs. But critics noted that the program could discriminate against companies that comply with President Donald Trump’s wishes, such as by paying lower prices for drugs.
The program, once a radical solution to US pharmaceutical regulation, has been abandoned and is a clear sign of the internal turmoil, feuds, and lack of consistent leadership that has beset the FDA since May’s last commissioner.
Early Approvals Give Way to Leadership Departures and Stalled Progress
A dozen of the 22 drugs received a voucher, with five of them being approved since Makary left the FDA in May. In some cases, the program helped shorten the time for drugs to receive approval by eight months or even longer.
But nothing has started with a voucher since Makary left, and a crucial part of the program, an executive council of political appointees that reviewed drugs and played a key role in expediting approvals, appears to have been dormant, according to internal documents.
The terms of the voucher program that is being delayed haven’t been reported before.
The pilot had drawn fierce criticism from regulatory experts over the handpicking of drugs and makeup of the council, which included former acting drug center director Tracy Beth Hoeg and former biologics chief Vinay Prasad. The two left the FDA earlier this year.
Applications Halted Despite Official Claims of Ongoing Review
Companies were informed of the FDA leadership’s decision that the agency will not proceed with the program but will maintain applications, according to a source who had first-hand knowledge of the process. These don’t move forward when it comes to companies submitting them, he said.
The program’s top administrator is leaving, while the program is quietly being phased out, said Rich Danker, a former assistant secretary at the Department of Health and Human Services. He did not refer to any new vouchers awarded.
The pilot is still active, and HHS is considering feedback from a public hearing on the pilot held in June and is working to tweak the structure, said HHS spokesperson Emily Hilliard.
The agency had not provided any comments on the dismissal of the program’s lead or the hiring of a new program coordinator.
Why the FDA Is Reportedly Shelving the Program
According to Reuters reporting published November 12, 2026, no new drugs have received vouchers since Marty Makary left the FDA in May.
Internal documents and sources familiar with the program indicate that the executive council responsible for overseeing the accelerated reviews has become inactive.
A source familiar with the process also reported that companies were informed that applications were no longer advancing, although submissions remained open.
The FDA’s future approach remains uncertain because HHS spokesperson Emily Hilliard stated that the pilot is still ongoing and that the agency is evaluating feedback from a public hearing.
The reported shelving of the Commissioner’s National Priority Voucher program represents an important development in US pharmaceutical regulation.
Although the FDA initiative was designed to accelerate access to innovative medicines, concerns about transparency, political influence and regulatory oversight have complicated its future.
The HHS position that the pilot remains ongoing also means its formal status should not be described as definitively terminated.For pharmaceutical companies, biotechnology developers and healthcare stakeholders, the situation highlights the importance of predictable regulatory pathways and independent scientific decision-making.


